Two Autophagy-Targeting Biotech Companies Advance Neurodegeneration Therapies to Human Trials

Two longevity-focused biotechnology companies have reached significant clinical milestones in developing therapies that target cellular autophagy mechanisms to treat neurodegenerative diseases, marking renewed momentum in addressing age-related brain disorders at their cellular origins.

Retro Biosciences (搜索)搜索该词条, the San Francisco-based company backed by a $180 million seed round from OpenAI (搜索)搜索该词条 CEO Sam Altman, has dosed the first participant in a Phase 1 clinical trial of its autophagy-enhancing drug candidate RTR242 (搜索)搜索该药品. The randomized, double-blind, placebo-controlled trial is being conducted in healthy volunteers at a specialized early-phase clinical unit in Adelaide, Australia.

Meanwhile, Cambridge-based Lysoway Therapeutics (搜索)搜索该词条 announced that its lead drug candidate LW-1017 (搜索)搜索该药品 is Phase I-ready, with first-in-human dosing planned for May 2026 in Australia. The company completed all IND-enabling studies with wide safety margins, clearing the path for human trials.

Targeting Cellular Waste Clearance Systems

Both companies are pursuing strategies that address the fundamental breakdown of cellular maintenance systems that occurs with aging. RTR242 (搜索)搜索该药品 is designed to restore lysosomal function, a core component of autophagy - the cell's waste-handling and recycling system. In healthy, younger cells, lysosomes (搜索)搜索该靶点 maintain an acidic environment that allows autophagy to break down damaged proteins and cellular debris.

As people age, particularly in neurodegenerative diseases such as Alzheimer's, lysosomes (搜索)搜索该靶点 lose acidity and efficiency, resulting in a buildup of toxic protein aggregates that place chronic stress on neurons and contribute to their dysfunction and eventual loss. Retro's approach aims to repair this decline at its source, reactivating the cell's own cleanup machinery rather than targeting the problem downstream.

LW-1017 (搜索)搜索该药品 takes a complementary approach by activating TRPML1 (搜索)搜索该靶点, an ion channel located within the lysosome that acts as a master switch for cellular cleanup. When functioning properly, TRPML1 helps coordinate autophagy and supports overall cellular resilience under stress. As we age, TRPML1 signaling becomes less efficient, weakening the brain's ability to maintain cellular order.

Promising Preclinical Results

Lysoway's preclinical data demonstrates the potential of targeting lysosomal ion channels. In aged models of Parkinson's disease (搜索)搜索该疾病, LW-1017 (搜索)搜索该药品 reduced toxic alpha-synuclein (搜索)搜索该靶点 buildup, preserved dopamine-producing neurons, and improved motor function. In Alzheimer's models, the compound lowered amyloid (搜索)搜索该靶点 and phosphorylated tau (搜索)搜索该靶点 levels while supporting cognitive performance. These effects were observed at low oral doses, indicating efficient brain penetration.

Using a structure-guided approach, Lysoway engineered LW-1017 (搜索)搜索该药品 to cross the blood-brain barrier effectively, achieving higher exposure in the brain than in the bloodstream. This balance allows the drug to engage its target where it matters most while maintaining wide safety margins.

Clinical Trial Design and Biomarker Strategy

Retro's Phase 1 study includes exploratory biomarkers tied to autophagy and lysosomal biology, providing the company's first opportunity to observe whether its mechanistic hypotheses translate into measurable biological signals in humans. The trial will assess standard safety and tolerability measures in addition to these mechanistic endpoints.

According to Yongchang Qiu, PhD, Founder and CEO of Lysoway Therapeutics (搜索)搜索该词条, "the deterioration of the autophagy-lysosomal pathway associated with aging is a primary factor leading to neurodegeneration (搜索)搜索该疾病." Qiu noted that while lysosomal ion channels serve as vital regulatory points within this system, they have traditionally been very challenging to target with medication, especially for central nervous system conditions.

Broader Pipeline Development

Both companies are developing additional programs beyond their lead candidates. Retro is working on cellular reprogramming and microglia therapeutics. In cellular reprogramming, the company is building on the Nobel Prize-winning discovery that mature cells can be reverted toward a more youthful, pluripotent state using transcription factors known as the Yamanaka factors. In collaboration with OpenAI (搜索)搜索该词条, Retro applied a specialized AI model trained for protein engineering to redesign key components of its reprogramming cocktail, resulting in engineered transcription factors that showed markedly higher efficiency in lab experiments.

Lysoway announced the nomination of a development candidate from its TMEM175查看药品详情 program, another lysosomal ion channel genetically linked to Parkinson's disease (搜索)搜索该疾病 risk. In August 2025, the company received a $2.93 million grant from The Michael J Fox Foundation (搜索)搜索该词条 to advance its TRPML1 (搜索)搜索该靶点 program for Parkinson's disease, supporting preclinical development and biomarker work.

Industry Implications

The advancement of both programs represents a shift in neurodegeneration (搜索)搜索该疾病 research toward targeting upstream cellular maintenance mechanisms rather than attempting to compensate for damage after it has occurred. Failures in cellular clearance are a common feature across many degenerative conditions, suggesting that if the biology proves tractable in humans, these approaches could have applications beyond neurodegeneration to other disorders where accumulated cellular damage plays a central role.

Retro's achievement of clinical-stage status follows reports that the company was preparing to raise as much as $1 billion to support its next phase of growth, indicating significant investor interest in longevity-focused therapeutic approaches.